Does cancer screening really not save lives?

From The Medical Republic, 30 October 2023: “Current evidence does not substantiate the claim that common cancer screening tests save lives.” As scientific mic drops go, it’s a doozy. The Australian government alone spends more than $400 million a year on screening programs for just three cancers – breast, bowel and cervical – and is Continue reading Does cancer screening really not save lives?

The science on Covid boosters

From The Saturday Paper, 4 September 2023: On May 5 this year, World Health Organization director-general Dr Tedros Adhanom Ghebreyesus declared the pandemic emergency downgraded from an acute global disaster into a more chronic, long-term affliction. Covid-19 became another in the long line of deadly pathogens that have seared their way into history, then faded Continue reading The science on Covid boosters

Daily statin cuts cardiovascular risk in HIV

From Medscape Medical News, 24 July 2023 Statins should be considered for primary prevention in people living with HIV who are at low-to-moderate risk of cardiovascular disease, according to final data from the REPRIEVE trial that show pitavastatin therapy is associated with a significantly lower risk of cardiovascular events than placebo. “There was a significant 35% lower Continue reading Daily statin cuts cardiovascular risk in HIV

Severe hydroxychloroquine non-adherence linked to worse SLE outcomes

From Rheumatology News, 25 May 2023: Regular testing of hydroxychloroquine levels in patients with systemic lupus erythematosus – especially those who are experiencing a disease flare – could help to identify patients who are not taking their treatment and are at risk of worse outcomes. Data presented at an international congress on systemic lupus erythematosus Continue reading Severe hydroxychloroquine non-adherence linked to worse SLE outcomes

Patient selection key to lowering placebo response rates in lupus clinical trials

From Rheumatology News, 13 June 2023: A major challenge for clinical trials in systemic lupus erythematosus (SLE) is how to get the placebo response rate down low enough that the effectiveness of a drug can actually be seen. Better patient selection may be the key. Speaking at an international congress on SLE, Joan Merrill, MD, Continue reading Patient selection key to lowering placebo response rates in lupus clinical trials

Strategies for complete B-cell depletion evolve for patients with lupus nephritis

From Rheumatology News, 13 June 2023: B cell–depleting therapies in patients with lupus nephritis have a higher likelihood of complete response if B cells are almost completely depleted, and strategies for achieving more complete B-cell depletion continue to be tested, according to evidence presented by Richard A. Furie, MD, at an international congress on systemic Continue reading Strategies for complete B-cell depletion evolve for patients with lupus nephritis

Australia bans all vapes except on prescription to stem use in children

From BMJ, 4 May 2023: The importation and sale of all e-cigarettes, regardless of whether they are labelled as containing nicotine or not, will soon be banned in Australia, unless they are supplied by prescription through a licensed pharmacist. The crackdown by the Australian government was announced amid concerns that a growing black market in Continue reading Australia bans all vapes except on prescription to stem use in children

‘You mean there’s nothing?’ The families fighting for their children with dementia

From the Guardian, 15 May 2023: In many ways, Ronin and Ethan are typical young boys. They love Hot Wheels toy cars, Shaun the Sheep, rude noises and pizza nights. Nine-year-old Ethan dotes on the family pets. Ronin, seven, is always booting a soccer ball around the back yard. “They’re two absolutely lovable friendly kids, Continue reading ‘You mean there’s nothing?’ The families fighting for their children with dementia

‘Hollywood skinny jab’: what do we know about anti-obesity drugs such as Ozempic in Australia?

From the Guardian, 8 April 2023: Dr Kathryn Williams has had patients cry when they go on anti-obesity drugs. “[They] say, ‘oh my God, this is the first time I haven’t felt hungry,’” says Williams, an endocrinologist at the University of Sydney, “because hunger is just something they have to live with every single day.” Continue reading ‘Hollywood skinny jab’: what do we know about anti-obesity drugs such as Ozempic in Australia?

Australia bans all vapes except on prescription to stem use in children

From the BMJ, 4 May 2023: The importation and sale of all e-cigarettes, regardless of whether they are labelled as containing nicotine or not, will soon be banned in Australia, unless they are supplied by prescription through a licensed pharmacist. The crackdown by the Australian government was announced amid concerns that a growing black market Continue reading Australia bans all vapes except on prescription to stem use in children